For the quarter ending 2026-03-31, ERAS had -$26,549K decrease in cash & cash equivalents over the period. -$27,419K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -183,440 | -29,092 | -30,612 | -64,842 |
| Depreciation and amortization | 723 | 743 | 755 | 1,609 |
| Stock-based compensation expense | 8,460 | 5,823 | 5,965 | 13,111 |
| In-process research and development expenses | 150,000 | 0 | 2,000 | 7,500 |
| Accretion on marketable securities, net | 746 | 580 | 1,022 | 3,485 |
| Realized gain from sales of marketable securities, net | 47 | - | - | - |
| Prepaid expenses and other current and long-term assets | -175 | -2,176 | 903 | -516 |
| Accounts payable | 1,182 | -2,048 | 1,366 | 1,195 |
| Accrued expenses and other current and long-term liabilities | -3,269 | 1,670 | 1,190 | -6,628 |
| Operating lease assets and liabilities, net | 421 | 403 | 397 | 1,062 |
| Net cash used in operating activities | -27,383 | -21,711 | -21,658 | -52,086 |
| Purchases of marketable securities | 253,170 | 42,230 | 41,540 | 67,204 |
| Maturities of marketable securities | 58,550 | 66,950 | 71,250 | 122,827 |
| Sales of marketable securities | 100,826 | - | - | - |
| In-process research and development | 150,000 | 0 | 4,000 | 5,500 |
| Purchases of property and equipment | 36 | 9 | 6 | 113 |
| Net cash (used in) provided by investing activities | -243,830 | 24,711 | 25,704 | 50,010 |
| Proceeds from issuance of common stock in underwritten offering | 258,750 | - | - | - |
| Issuance costs associated with underwritten offering | 16,044 | - | - | - |
| Proceeds from the exercise of stock options | 1,958 | 255 | 41 | 76 |
| Proceeds from issuance of common stock under the employee stock purchase plan | - | 320 | 0 | 404 |
| Net cash provided by financing activities | 244,664 | 575 | 41 | 480 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -26,549 | 3,575 | 4,087 | -1,596 |
| Cash, cash equivalents and restricted cash at beginning of the period | 74,213 | 70,638 | 68,147 | - |
| Cash, cash equivalents and restricted cash at end of the period | 47,664 | 74,213 | 70,638 | - |
Erasca, Inc. (ERAS)
Erasca, Inc. (ERAS)